---
layout: post
title: "Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:02 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09608
original_published: 2022-05-05 00:00:00 +0000
significance: 8.00
---

# Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 05, 2022 00:00 UTC
**Document Number:** 2022-09608

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies." This draft guidance describes the FDA's recommendations regarding clinical pharmacology considerations for conducting human radiolabeled mass balance studies, including deciding whether and when to conduct the study, designing the study, and reporting results.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/05/2022-09608/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-09608

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
